 Protalix BioTherapeutics Inc NYSE: PLX and Chiesi Global Rare Diseases, a unit of Chiesi Farmaceutici S.p.A., have announced topline data from the BALANCE Phase 3 trial evaluating pegunigalsidase alfa PRX102 for Fabry disease. 